Antibody Information

General Information of This Antibody
Antibody ID
ANI0FCKKG
Antibody Name
Promiximab
Synonyms
HPAB-N0187-YC
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Neural cell adhesion molecule 1 (NCAM1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Promiximab-MMAE [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 78.90% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (2.5 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H69 CDX model
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.50% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (5 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H69 CDX model
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H526 CDX model
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 91.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H526 CDX model
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H69 CDX model
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H526 CDX model
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.32 nM
Positive CD56 expression (CD56 +++/++)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
5.23 nM
Positive CD56 expression (CD56 +++/++)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
19.24 nM
Positive CD56 expression (CD56 +++/++)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Lung small cell carcinoma NCI-H524 cells CVCL_1568
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1200 nM Negative CD56 expression (CD56 -)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Normal NK cells Homo sapiens
References
Ref 1 Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models. J Drug Target. 2018 Dec;26(10):905-912. doi: 10.1080/1061186X.2018.1450413. Epub 2018 Apr 13.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.